Investor Overview

Corporate Profile
Verastem, Inc. (NASDAQ:VSTM) is a biopharmaceutical company focused on discovering and developing drugs to improve outcomes for patients with cancer. Verastem’s product candidates utilize a multi-faceted approach to treat cancer by reducing cancer stem cells, enhancing anti-tumor immunity, and modulating the local tumor microenvironment. The company’s most advanced clinical product candidates are the Focal Adhesion Kinase inhibitors, VS-6063 and VS-4718, and the dual PI3K/mTOR inhibitor, VS-5584.
Stock Quote
VSTM (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$1.30
Change (%) Stock is Down 0.01 (0.76%)
Volume52,422
Data as of 07/22/16 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent News More >>
DateTitle 
07/06/16Verastem to Present at Cantor Fitzgerald’s 2nd Annual Healthcare Conference
BOSTON--(BUSINESS WIRE)--Jul. 6, 2016-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer, today announced that the company will present at Cantor Fitzgerald’s 2nd Annual Healthcare Conference on Wednesday, July 13th at 3:30 PM Eastern Time at Le Parker Meridien New York. A live audio webcast of the presentation will be available on the company’s website at www.verastem.com. An archived presentation ... 
Printer Friendly Version
07/05/16Study Published in Nature Medicine Highlights Potential Role of FAK Inhibition in Pancreatic Cancer
- FAK Inhibition Renders Previously Unresponsive Pancreatic Tumors Responsive to Chemo- and Immunotherapy – - Preclinical Results Support Ongoing Phase 1 Clinical Trial in Patients with Pancreatic Cancer – BOSTON--(BUSINESS WIRE)--Jul. 5, 2016-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer, today announced the publication of preclinical research in the journal Nature Medicine by the Company’... 
Printer Friendly Version
06/14/16Verastem Announces Changes to its Board of Directors
BOSTON--(BUSINESS WIRE)--Jun. 14, 2016-- Verastem, Inc. (NASDAQ: VSTM), focused on discovering and developing drugs to treat cancer, today announced several changes to the Company’s Board of Directors. Michael Kauffman, MD, PhD, who has served as a director since November 2012, will become Lead Director and Bruce J. Wendel will join the Board as an independent director. “Bruce is a proven leader whose experience building companies and brin... 
Printer Friendly Version
06/01/16Verastem to Present at Upcoming Investor Conferences
BOSTON--(BUSINESS WIRE)--Jun. 1, 2016-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer, today announced that the company will present at the following upcoming investor conferences: The Jefferies 2016 Healthcare Conference on Thursday, June 9 at 9:30 a.m. ET at the Grand Hyatt in New York City The JMP Securities Life Sciences Conference on Wednesday, June 22 at 10:0... 
Printer Friendly Version
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever Verastem Inc posts new information to the site. Just enter your e-mail address and click Submit.
 

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.